Latest Intellectual Property News

IPH Limited has clarified that its FY25 underlying earnings aligned closely with market consensus, addressing ASX concerns amid a notable share price drop post-results. The company attributes the share price movement to external operational challenges rather than earnings surprises.

Nanoveu’s subsidiary EMASS has demonstrated a remarkable leap in drone endurance using its ECS-DoT ultra-low-power AI chip, achieving average flight time extensions of 60% across multiple drone types in over 300 simulated trials.

Iondrive Limited has secured a binding agreement with Colt Recycling LLC to test its innovative deep eutectic solvent technology for recovering rare earth elements from electronic waste, aiming to scale operations in North America.

Amaero Ltd has locked in a five-year exclusive agreement to supply spherical refractory and titanium alloy powders to Titomic, bolstering advanced manufacturing capabilities for defense and aerospace sectors.

Titomic Limited and Amaero Ltd have entered a five-year exclusive agreement to supply high-quality titanium and refractory powders, bolstering cold spray additive manufacturing for defense and aerospace sectors.

Gateway Mining has appointed seasoned geologist Richard Pugh as CEO, aiming to leverage his deep Yandal Project expertise to fast-track exploration and resource expansion.

Osteopore Limited has established OsteoRx, a new special purpose vehicle, with an initial AUD 0.5 million investment to accelerate breakthroughs in cellular regenerative medicine. This strategic move integrates a controlling stake in US-based RxCell Inc, expanding Osteopore’s footprint in the fast-growing stem cell market.

Recce Pharmaceuticals reported a 21% increase in net loss to $21.4 million for FY2025, driven by intensified R&D spending. The company secured key regulatory approvals for Phase 3 trials of its lead anti-infective gel and bolstered its financial position with significant capital raises and grants.

Holista Colltech reports a sharp 70% reduction in net loss and an 8.6% revenue rise, driven by strong supplements sales and a landmark collagen partnership with Regenerex Pharma.

4DS Memory Limited posted a $9.68 million loss for FY2025 as it advanced its 20nm ReRAM technology, encountering manufacturing setbacks that prompted a detailed root cause analysis. The company secured $8 million in capital to support ongoing development and strategic partnerships.

Argent BioPharma reported a net loss of A$17.84 million for FY2025, reflecting a strategic pivot towards core drug development and clinical advancement. The company secured key EU approvals and raised significant capital to support its neuro-immune modulatory pipeline.

Osteopore Limited reported a 6% increase in revenue to $1.56 million for the half-year ended June 2025, alongside a slight rise in net loss driven by expanded product development and compliance costs. The company secured key regulatory approvals and broadened its distribution footprint in Asia and the US.